By Fineline Cube 
Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing application to the Hong Kong Stock Exchange for an initial public offering (IPO), advancing its pipeline of siRNA therapies targeting coagulation disorders, cardiometabolic diseases, and obesity.
Company Profile
| Parameter | Detail |
|---|---|
| Founded | 2021 |
| Stage | Global clinical-stage biotechnology |
| Therapeutic Focus | siRNA therapies for coagulation disorders, cardiometabolic diseases, and obesity |
| IPO Status | Hong Kong Stock Exchange listing application submitted |
| Pipeline Size | 21 programs in development |
Lead Programs Portfolio
SRSD107 – Factor XI-Targeting siRNA
- Target: Factor XI (coagulation pathway)
- Stage: Phase II multi-regional clinical trials
- Geographies: Europe and China (additional Phase II study in China)
- Partnership: Global co-development and commercialization collaboration with CRISPR Therapeutics (Nasdaq: CRSP)
- Indication: Coagulation disorders
SRSD216 – Lp(a)-Targeting siRNA
- Target: Lipoprotein(a) [Lp(a)]
- Stage: Multi-regional Phase IIa trial
- Geographies: China and United States
- Differentiation: Novel approach to cardiovascular risk reduction
- Indication: Cardiometabolic diseases
SRSD384 – INHBE-Targeting siRNA
- Target: INHBE (inhibin beta E subunit)
- Stage: Preclinical; progressing toward IND filing
- Data Status: Positive preclinical results reported
- Indication: Obesity
Strategic Partnership – CRISPR Therapeutics
- Collaboration Type: Global co-development and commercialization
- Asset: SRSD107 (Factor XI-targeting siRNA)
- Partner: CRISPR Therapeutics (Nasdaq: CRSP)
- Strategic Value: Leverages CRISPR’s global infrastructure and expertise
- Financial Structure: Terms not disclosed; likely includes upfront, milestones, and royalties
Market Opportunity Analysis
siRNA Therapeutics Landscape
- Technology Validation: siRNA platform proven with multiple approved products (e.g., inclisiran, givosiran)
- Dosing Advantage: Infrequent subcutaneous administration improves patient compliance
- Target Specificity: High specificity reduces off-target effects
- Market Growth: Global siRNA therapeutics market projected to exceed $10 billion by 2030
Therapeutic Areas
- Coagulation Disorders: Factor XI inhibition offers anticoagulation without bleeding risk
- Cardiometabolic: Lp(a) represents emerging high-value cardiovascular target
- Obesity: Massive market opportunity with limited effective long-term treatments
IPO Strategic Rationale
Capital Requirements
- Clinical Development: Funding needed for global Phase II/III trials across multiple programs
- Manufacturing Scale-up: Investment required for GMP manufacturing capacity
- Commercial Infrastructure: Building capabilities for potential product launches
- Pipeline Expansion: Resources for advancing additional preclinical candidates
Market Timing
- Hong Kong Biotech Market: Favorable environment for innovative biotech IPOs
- siRNA Momentum: Strong investor interest in RNA-targeting technologies
- Global Expansion: Public listing supports international development strategy
Competitive Positioning
- Technology Platform: Proprietary siRNA delivery and optimization capabilities
- Pipeline Breadth: 21 programs provide diversification across therapeutic areas
- Global Strategy: Multi-regional trials position for worldwide regulatory submissions
- Partnership Leverage: CRISPR collaboration enhances credibility and resources
Forward‑Looking Statements
This brief contains forward-looking statements regarding IPO plans, clinical development, and partnership arrangements. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, and market conditions.-Fineline Info & Tech